Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleRadionuclide Therapy

Analysis of Radiometry on Patients Undergoing Radioactive Iodine Therapy

Pietro Paolo de Barros, Tatiane Sabriela Cagol Camozzato, Tiago Jahn, Flávio Augusto Penna Soares, Letícia Machado da Silva, Jacqueline de Aguiar Soares and Marco Antonio Neiva Koslosky
Journal of Nuclear Medicine Technology March 2021, 49 (1) 75-81; DOI: https://doi.org/10.2967/jnmt.120.246512
Pietro Paolo de Barros
1Federal Institute of Education, Science, and Technology of Santa Catarina–IFSC, Florianópolis, Santa Catarina, Brazil; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiane Sabriela Cagol Camozzato
1Federal Institute of Education, Science, and Technology of Santa Catarina–IFSC, Florianópolis, Santa Catarina, Brazil; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiago Jahn
2Bionuclear Clinic, Florianópolis, Santa Catarina, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flávio Augusto Penna Soares
1Federal Institute of Education, Science, and Technology of Santa Catarina–IFSC, Florianópolis, Santa Catarina, Brazil; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Letícia Machado da Silva
1Federal Institute of Education, Science, and Technology of Santa Catarina–IFSC, Florianópolis, Santa Catarina, Brazil; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline de Aguiar Soares
1Federal Institute of Education, Science, and Technology of Santa Catarina–IFSC, Florianópolis, Santa Catarina, Brazil; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Antonio Neiva Koslosky
1Federal Institute of Education, Science, and Technology of Santa Catarina–IFSC, Florianópolis, Santa Catarina, Brazil; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Patient’s and researcher’s positions (cross and dot, respectively) in both therapeutic rooms. Lead screen used to shield radiation is represented as striped line and was positioned before measurement of dose rate, reducing influence of other patients.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Variables considered and their influence on dose rate. Coefficients and SDs are presented, as well as results of t test and significance.

Tables

  • Figures
    • View popup
    TABLE 1

    Effective Half-Life and Total Length of Stay According to Different Variables

    Variablen%Effective half-life (h)Total length of stay (h)
    MeanSDMeanSD
    Sex
     Female14973.0412.493.2414.284.92
     Male5526.9612.943.4117.806.17
    Age (y)
     <2010.4913.450.0015.110.00
     20–397737.7512.863.3115.055.26
     40–6411455.8812.343.2715.465.84
     ≥65125.8813.523.3514.223.82
    BMI
     Underweight20.9811.741.4313.431.58
     Normal6330.8812.123.1815.1115.11
     Overweight9848.0412.713.5515.5615.56
     Obese4120.1013.192.7514.7214.72
    Activity (MBq)
     3,70013867.6512.112.6611.991.63
     5,5505125.0013.664.0319.911.82
     7,400136.3713.774.9628.191.34
     9,25020.9813.490.3635.601.89
    rhTSH use
     No12360.7813.573.5816.735.30
     Yes8039.2211.132.0312.925.00
    Ingested-liquid volume (L)
     0–2115.3914.422.0114.112.89
     2–46732.8413.153.3216.216.43
     4–67737.7512.013.4314.795.11
     6–83718.1411.862.8314.465.21
     8–1083.9213.532.4416.035.04
     >1031.4713.452.4014.323.72
    Total/mean time204100.0012.613.2815.235.50
    • View popup
    TABLE 2

    Coefficients and Their Significance According to Different Variables

    VariableCoefficientSDt testPConclusion
    Female
     Age0.0390.0510.7600.448Not significant
     Weight−0.1460.038−3.8020.000Significant
     Height12.44110.9411.1370.256Not significant
     Activity0.3260.02512.8020.000Significant
     rhTSH−4.0411.142−3.5390.000Significant
     Ingested-liquid volume−2.2710.404−5.6190.000Significant
     Time−1.4460.100−14.3930.000Significant
    Male
     Age0.1570..1351.1640.247Not significant
     Weight−0.1540.054−2.8380.005Significant
     Height19.41721.2280.9150.362Not significant
     Activity0.3280.0556.0120.000Significant
     rhTSH−9.3413.907−2.3910.019Significant
     Ingested-liquid volume−0.6671.164−0.5730.568Not significant
     Time−2.4280.278−8.7270.000Significant
    Normal BMI
     Age−0.0280.081−0.3490.728Not significant
     Sex3.5482.2081.6070.110Not significant
     Activity0.3600.0409.0640.000Significant
     rhTSH−5.3301.643−3.2430.001Significant
     Ingested-liquid volume−2.5740.818−3.1480.002Significant
     Time−1.5970.177−9.0100.000Significant
    Overweight
     Age0.0920.0801.1490.252Not significant
     Sex4.0372.2981.7570.081Not significant
     Activity0.3110.03010.4600.000Significant
     rhTSH−5.4302.441−2.2240.028Significant
     Ingested-liquid volume−1.8380.647−2.8420.005Significant
     Time−1.7440.180−9.6820.000Significant
    Obese
     Age0.1750.1701.0330.305Not significant
     Sex3.6974.2440.8710.387Not significant
     Activity0.3720.0596.2900.000Significant
     rhTSH4.1942.9621.4160.162Not significant
     Ingested-liquid volume−1.7870.991−1.8040.076Not significant
     Time−1.6840.219−7.7020.000Significant
    20–39 y old
     Sex9.7614.8312.0210.045Significant
     Weight−0.1730.121−1.4240.157Not significant
     Height−14.30423.165−0.6180.538Not significant
     Activity0.2680.0406.7180.000Significant
     rhTSH−2.6691.919−1.3900.167Not significant
     Ingested-liquid volume−2.8320.944−3.0010.003Significant
     Time−1.7020.201−8.4800.000Significant
    40–64 y old
     Sex1.4852.5450.5840.560Not significant
     Weight−0.1280.035−3.6980.000Significant
     Height25.32311.5002.2020.029Significant
     Activity0.3510.03111.2880.000Significant
     rhTSH−5.8191.640−3.5480.000Significant
     Ingested-liquid volume−2.2560.539−4.1830.000Significant
     Time−1.5850.141−11.2160.000Significant
    ≥65 y old
     Sex−17.9994.331−4.1560.000Significant
     Weight0.1580.1501.0480.299Not significant
     Height71.85920.4253.5180.001Significant
     Activity0.0180.0029.4590.000Significant
     rhTSH−0.4642.598−0.1790.859Not significant
     Ingested-liquid volume−4.1740.707−5.9060.000Significant
     Time−0.0130.003−4.5300.000Significant
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 49 (1)
Journal of Nuclear Medicine Technology
Vol. 49, Issue 1
March 1, 2021
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of Radiometry on Patients Undergoing Radioactive Iodine Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Analysis of Radiometry on Patients Undergoing Radioactive Iodine Therapy
Pietro Paolo de Barros, Tatiane Sabriela Cagol Camozzato, Tiago Jahn, Flávio Augusto Penna Soares, Letícia Machado da Silva, Jacqueline de Aguiar Soares, Marco Antonio Neiva Koslosky
Journal of Nuclear Medicine Technology Mar 2021, 49 (1) 75-81; DOI: 10.2967/jnmt.120.246512

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Analysis of Radiometry on Patients Undergoing Radioactive Iodine Therapy
Pietro Paolo de Barros, Tatiane Sabriela Cagol Camozzato, Tiago Jahn, Flávio Augusto Penna Soares, Letícia Machado da Silva, Jacqueline de Aguiar Soares, Marco Antonio Neiva Koslosky
Journal of Nuclear Medicine Technology Mar 2021, 49 (1) 75-81; DOI: 10.2967/jnmt.120.246512
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Direct Correlation of Tumor Absorbed Dose with Overall Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu Prostate-Specific Membrane Antigen
  • Survey of Clinical Protocols for the Use of 177Lu-PSMA-617 in the United States
  • First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Show more Radionuclide Therapy

Similar Articles

Keywords

  • nuclear medicine
  • radiation protection
  • iodine radioisotopes
  • half-life
  • therapy
SNMMI

© 2025 SNMMI

Powered by HighWire